5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngwe Tun, Mya Myat, Sakura, Takaya, Sakurai, Yasuteru, Kurosaki, Yohei, Inaoka, Daniel Ken, Shioda, Norifumi, Smith, Chris, Yasuda, Jiro, Morita, Kouichi, Kita, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043503/
https://www.ncbi.nlm.nih.gov/pubmed/35477500
http://dx.doi.org/10.1186/s41182-022-00422-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043503/
https://www.ncbi.nlm.nih.gov/pubmed/35477500
http://dx.doi.org/10.1186/s41182-022-00422-7

Ejemplares similares